The study aimed to identify the usefulness of telemonitoring to detect and manage acute exacerbation of COPD (AECOPD).
Telemonitoring can reduce emergency department (ED) visits and exacerbation-related readmissions, as well as acute exacerbation-related hospital days in chronic obstructive pulmonary disease (COPD), according to a recent analysis out of China.
The results also showed improvements in mortality and the St. George's Respiratory Questionnaire (SGRQ) score.
Acute exacerbation of COPD (AECOPD), where there is an acute worsening of respiratory symptoms affecting health status and lung function, account for the bulk of health care costs related to COPD (about 70%). In AECOPD, patients, many of whom are older, often have difficulty recognizing early signs that the disease is getting worse based on symptoms and cannot respond quickly to manage their health, indicating an urgent need to develop effective options to help patients recognize the early onset of AECOPD.
The authors said they conducted the review and meta-analysis in order to compare the evidence on the effectiveness of telemonitoring in patients with a history of past AECOPD, compared with patients without the intervention.
The authors searched PubMed, Embase, and the Cochrane Library for randomized controlled trials published from 1990 to May 2020. Primary endpoints included ED visits and exacerbation-related readmissions and results were analyzed with multiple regression analysis.
Out of 505 studies, 17 were selected for the final analysis (N = 3001); each included telemonitoring and a control group.
The telemonitoring may have included various forms of telemedicine: telehealthcare, telerehabilitation, teleconsultation, telecare, telehealth, mobile tool, apps, or a call center. The studies also had to include a telemonitoring device to monitor significant parameters or symptoms.
The control group had usual care without the use of any telemonitoring.
Telemonitoring was found to reduce:
SGRQ scores also showed improvement (MD, −3.72; 95% CI, −7.18 to −0.26)
However, telemonitoring did not make a statistically significant difference in all-cause readmissions, the rate of exacerbation-related readmissions, all-cause hospital days, time to first hospital readmission, anxiety and depression, and exercise capacity.
A subgroup analysis by observation period showed that longer periods of telemonitoring (12 months or more) was more effective in reducing readmissions.
Reference
Lu, JW, Wang Y, Sun Y, et al. Effectiveness of telemonitoring for reducing exacerbation occurrence in COPD patients with past exacerbation history: A systematic review and meta-analysis. Front. Med. Published online September 10, 2021. doi: 10.3389/fmed.2021.720019
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Certain genes have been linked to significant weight reduction in obesity treatment; research boosts plaintiffs’ cases against Johnson & Johnson for their talc-based baby powder; proposed legislation aims to address concerns following Alabama Supreme Court ruling on embryos.
Read More
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Certain genes have been linked to significant weight reduction in obesity treatment; research boosts plaintiffs’ cases against Johnson & Johnson for their talc-based baby powder; proposed legislation aims to address concerns following Alabama Supreme Court ruling on embryos.
Read More
2 Commerce Drive
Cranbury, NJ 08512